These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 8091651)
1. The spread of a replication-competent MuLV retroviral vector can be efficiently blocked by deletion variants. Nouvel P; Panthier JJ; Condamine H Virology; 1994 Oct; 204(1):180-9. PubMed ID: 8091651 [TBL] [Abstract][Full Text] [Related]
2. Defective and wild-type human T-cell leukemia virus type I proviruses: characterization of gene products and trans-interactions between proviruses. Shuh M; Hill SA; Derse D Virology; 1999 Sep; 262(2):442-51. PubMed ID: 10502522 [TBL] [Abstract][Full Text] [Related]
3. Comparisons of defective HTLV-I proviruses predict the mode of origin and coding potential of internally deleted genomes. Hill SA; Shuh M; Derse D Virology; 1999 Oct; 263(2):273-81. PubMed ID: 10544101 [TBL] [Abstract][Full Text] [Related]
4. Virofection: a one-step procedure for using replication-defective retrovirus vectors. Flamant F; Samarut J Virology; 1995 Aug; 211(1):234-40. PubMed ID: 7645216 [TBL] [Abstract][Full Text] [Related]
5. Defective retroviral endogenous RNA is efficiently transmitted by infectious particles produced on an avian retroviral vector packaging cell line. Ronfort C; Girod A; Cosset FL; Legras C; Nigon VM; Chebloune Y; Verdier G Virology; 1995 Feb; 207(1):271-5. PubMed ID: 7871738 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of melanoma-associated antigen expression and ecotropic retrovirus production in B16BL6 melanoma cells transfected with major histocompatibility complex class I genes. Li M; Muller J; Xu F; Hearing VJ; Gorelik E Cancer Res; 1996 Oct; 56(19):4464-74. PubMed ID: 8813142 [TBL] [Abstract][Full Text] [Related]
7. Gene transfer in bovine blastocysts using replication-defective retroviral vectors packaged with Gibbon ape leukemia virus envelopes. Kim T; Leibfried-Rutledge ML; First NL Mol Reprod Dev; 1993 Jun; 35(2):105-13. PubMed ID: 8391277 [TBL] [Abstract][Full Text] [Related]
8. Analysis of ALV-based packaging cell lines for production of contaminant defective viruses. Girod A; Cosset FL; Verdier G; Ronfort C Virology; 1995 Jun; 209(2):671-5. PubMed ID: 7778301 [TBL] [Abstract][Full Text] [Related]
9. A new defective retroviral vector system based on the Bryan strain of Rous sarcoma virus. Boerkoel CF; Federspiel MJ; Salter DW; Payne W; Crittenden LB; Kung HJ; Hughes SH Virology; 1993 Aug; 195(2):669-79. PubMed ID: 8393241 [TBL] [Abstract][Full Text] [Related]
10. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment. Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095 [TBL] [Abstract][Full Text] [Related]
11. Inducible gene expression of the human immunodeficiency virus LTR in a replication-incompetent herpes simplex virus vector. Warden MP; Weir JP Virology; 1996 Dec; 226(1):127-31. PubMed ID: 8941330 [TBL] [Abstract][Full Text] [Related]
12. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas. Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566 [TBL] [Abstract][Full Text] [Related]
13. A murine leukemia virus derived retroviral vector with a rat VL30 packaging psi sequence. Torrent C; Wang P; Darlix JL Bone Marrow Transplant; 1992; 9 Suppl 1():143-7. PubMed ID: 1324044 [TBL] [Abstract][Full Text] [Related]
14. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination. Yu SS; Han E; Hong Y; Lee JT; Kim S; Kim S Gene Ther; 2003 Apr; 10(8):706-11. PubMed ID: 12692599 [TBL] [Abstract][Full Text] [Related]
15. Effects of the gag region on genome stability: avian retroviral vectors that contain sequences from the Bryan strain of Rous sarcoma virus. Federspiel MJ; Hughes SH Virology; 1994 Sep; 203(2):211-20. PubMed ID: 8053145 [TBL] [Abstract][Full Text] [Related]
16. Transmission of endogenous VL30 retrotransposons by helper cells used in gene therapy. Chakraborty AK; Zink MA; Hodgson CP Cancer Gene Ther; 1994 Jun; 1(2):113-8. PubMed ID: 7621242 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1 derived vector system. Chang LJ; Urlacher V; Iwakuma T; Cui Y; Zucali J Gene Ther; 1999 May; 6(5):715-28. PubMed ID: 10505094 [TBL] [Abstract][Full Text] [Related]
18. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. Ni Y; Sun S; Oparaocha I; Humeau L; Davis B; Cohen R; Binder G; Chang YN; Slepushkin V; Dropulic B J Gene Med; 2005 Jun; 7(6):818-34. PubMed ID: 15693055 [TBL] [Abstract][Full Text] [Related]
19. Recombinant equine arteritis virus as an expression vector. de Vries AA; Glaser AL; Raamsman MJ; Rottier PJ Virology; 2001 Jun; 284(2):259-76. PubMed ID: 11384225 [TBL] [Abstract][Full Text] [Related]
20. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Curran MA; Kaiser SM; Achacoso PL; Nolan GP Mol Ther; 2000 Jan; 1(1):31-8. PubMed ID: 10933909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]